Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The pharmaceutical giant Eli Lilly announced last week that its investigational drug, orforglipron, proved effective in a third late-stage clinical trial
Get Help
Chugai and Lilly published the preclinical pharmacology data of this molecule together, and Lilly is running Phase III studies on orforglipron for the treatment of Type 2 diabetes and for weight management in adults with obesity or overweight with at least one weight-related medical problem
doi: 10.1186/s12967-024-05539-3 39 LeppkesMLindemannAGweinSPaulusSRothDHartungAet al
,aspect=ignore)
US$ 27.86
,aspect=ignore)
,aspect=ignore)
US$ 24.57
US$ 26.68
,aspect=ignore)
US$ 28.25
,aspect=ignore)
US$ 21.62
